Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

By sjmartinez • May 4, 2025

Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder M, Spitzweg C, Worden FP, Wirth L, Ho A. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 2025 Apr 30:S2213-8587(25)00064-6. doi: 10.1016/S2213-8587(25)00064-6. Epub ahead of print. PMID: 40318680.

Tags: Endocrinology, Harbor UCLA, Publications

Related Posts

Integrated chromatin and transcriptomic profiling reveals sex-specific mechanisms of gene regulation in hepatic nutrient responses

Zhang Z, Su V, Wiese CB, Cheng L, Wang D, Cui Y, Kallapur A, Kim J, Wu X, Tran PH, Zhou Z, Casero D, Li[...]

Colliding crises: The global diabetes pandemic meets climate change-A scoping review

Perez JS, Hudson H, Araneta J, Bedell B, Aikins AD, Dugas LR, Eid M, Eshac Y, Fariduddin M, Fariduddin M, Jong K, Kapwata T, Luke[...]

Glymphatic system impairment in type II diabetes mellitus adults

Roy B, Lubera V, Singh KR, Singh A, Karunamuni DR, Kosoyan DE, Carrier M, Choi SE, Freeby MJ, Kumar R. Glymphatic system impairment in type[...]